MUSC Children's Hospital

We're all about children!

Current Research Activities

Researchers at MUSC Children's Hospital are continually striving to make advancements in medicine and technology. It's our ongoing committment to keep children healthy and free of disease. Here are some of our current research activities.

Pediatrics, A Phase 3, Double-Blind, Multi-Center, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)
$51, 770 from Corus Pharma
April 2005 through December 2005
PI= Michael Bowman

Pediatrics, Incorporating Environmental Management of Asthma into Pediatric Medical and Nursing Education
$8, 750 from National Environment Education and Training Foundation
May 2004 through October 2005
PI= James Roberts

Pediatrics, Advances in Autism Spectrum Disorders
$3,000 from Shire Pharmaceutical Development
December 2004 through December 2005
PI= Jane Charles

Pediatrics, External, Continuous, Subcutaneous Infusion of Insulin Aspart (NovoLog) versus Insulin Lispro (Humalog)
An Open-Label, Randomized, Parallel-Group, Multi-Center Study in Children and Adolescents with Type 1 Diabetes
$33,474 from Novo Nordisk Pharmacy
April 2005 through April 2006
PI= Yaw Appiagyei-Dankah

Pediatrics, Optimizing Primary Stroke Prevention in SC Anemia Children-STOPII
$39,325 from Medical College of Georgia
July 2004 through June 2005
PI= Clark Brown

Pediatric Hydroxyurea Phase III Clinical Trial - Clinical Center
$92,107 from national Heart, Lung and Blood Institute
January through December 2005
PI = Julio Barredo

A Phase III, Multi-Center, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Diesease Who Have Had < 2 Acute Sickle-Related Painfull Crises within the Preceeding 12 Months
$196,258 from Quintiles Pacific Inc.
January 2005 through September 2006

Multidisciplinary Crisis Prevention Program
$30,000 from Lowcountry Children
October 2003 through September 2005
PI = David M. Habib

Reactive Nitrogen and Cerebral Ischemic Injury
$193,179 from National Institute of Neurological Disorders and Stroke
April 2000 through March 2005
PI = Mush Khan

Neurobiology of Disease in Children Conference
$43,000 from National Institute of Neurological Disorders and Stroke
April 2004 through March 2005
PI = Bernard L. Maria

An Open Controlled, Randomized, Comparative, Phase IIIb Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithkline Biologicals Combined Hepatitis A and Hepatitis B Vaccine
$71,030 from GlaxoSmithkline
April 2003 through March 2005
PI = Sandra L. Fowler, MD

Pediatric Hydroxyurea Phase III Clinical Trial - Clinical Center
$65,000 from National Heart, Lung and Blood Institute
June 2000 through July 2006
PI = Julio Barredo, MD

Phase II, Randomized, Non-Comparative Trial of Irinotecan and Carboplatin vs. Irinotecan in Subjects 1-21 Years of Age with Refractory Solid Tumors (Study No. CA124-002-048)
$40,875 from Bristol Myers Squibb
March 2003 through January 2005
PI = Julio Barredo, MD

A Phase II Study to Evaluate PEN 110-Treated Red Blood Cells in Chronically Transfused Patients
$178,300 from James E. and Pamela Knowles
January 2003 through December 2005
PI = Clark Brown, MD

Pediatric Hydroxyurea Phase III Clinical Trial - Clinical Center
$75,000 from National Heart, Lung and Blood Institute
September 2000 through July 2006
PI = Julio Barredo, MD

Pediatric Hydroxyurea Phase III Clinical Trial - Clinical Center
$3,622 from National Heart, Lung and Blood Institute
September 2000 through July 2006
PI = Miguel R. Abboud